(S,R,S)-AHPC-Boc is primarily used in the field of medicinal chemistry and drug development as a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs). PROTACs are a novel class of bifunctional molecules designed to selectively degrade target proteins within cells, offering a promising approach for treating diseases caused by abnormal protein activity, such as cancer and neurodegenerative disorders.

This compound is particularly valuable due to its role in linking the target protein-binding ligand to the E3 ubiquitin ligase-recruiting moiety, which is essential for the ubiquitin-proteasome system to degrade the protein of interest. Its Boc (tert-butoxycarbonyl) protecting group ensures stability during synthesis, allowing for precise control over the chemical reactions involved in constructing PROTAC molecules.

Researchers leverage (S,R,S)-AHPC-Boc to develop highly specific and potent degraders of disease-causing proteins, advancing the field of targeted protein degradation and enabling the exploration of new therapeutic strategies.